Clinical Trails

Results from the Phase 3 TRIDENT trial showed that starting Tumor Treating Fields (TTFields) at the beginning of chemoradiotherapy did not significantly improve overall survival compared with starting the therapy during the standard maintenance phase for patients with newly diagnosed glioblastoma. The study enrolled 981 patients who received TTFields either alongside radiation and temozolomide chemotherapy […]

A Phase 2 study presented at the 2026 ESMO Gynaecological Cancers Congress showed that the combination of palbociclib (Ibrance) and anastrozole may provide an effective treatment option for patients with recurrent or metastatic estrogen receptor (ER)-positive, low-grade endometrioid endometrial cancer. Among 25 patients enrolled, the objective response rate was 32% at three months, including one

Bulumtatug fuvedotin (9MW2821), a Nectin-4–targeting antibody-drug conjugate, showed promising activity in patients with recurrent or metastatic cervical cancer who had progressed after platinum-based chemotherapy.. In a phase 1/2 study of 53 patients, 73.6% experienced tumor shrinkage. The confirmed overall response rate was 32.08%, including one complete response and 16 partial responses. Disease control was achieved

Results from the phase 3 POD1UM-303/InterAACT 2 trial have established retifanlimab (Zynyz) combined with carboplatin and paclitaxel as a new first-line treatment for advanced squamous cell carcinoma of the anal canal (SCAC). The findings led the FDA to approve the regimen in May 2025 for patients with inoperable recurrent or metastatic disease who have not

A Phase 3 clinical trial tested sunvozertinib (Zegfrovy), a once-daily oral drug, against standard chemotherapy as first-line treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. The results showed that sunvozertinib worked better than chemotherapy. Patients taking the drug lived longer without their cancer getting worse (about 10.3 months vs. 7.5

Data from the phase 3 SENTRY trial showed that adding selinexor (Xpovio) to ruxolitinib (Jakafi) significantly improved spleen responses in patients with JAK inhibitor-naive myelofibrosis. The study met one of its two co-primary endpoints, with 49.8% of patients receiving the combination achieving at least a 35% reduction in spleen volume at week 24, compared with

Early results from an ongoing phase 1/2 clinical trial show promising activity for vopimetostat, an oral PRMT5 inhibitor, when combined with RAS-targeted therapies in patients with advanced, previously treated pancreatic cancer that has an MTAP deletion. The strongest results were seen with vopimetostat plus daraxonrasib in patients with RAS-mutant pancreatic cancer. Among 12 evaluable patients,

The phase 3 RECITE trial evaluated romiplostim (Nplate) versus placebo for chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers receiving oxaliplatin-based chemotherapy. CIT often forces chemotherapy delays or dose reductions, potentially compromising treatment effectiveness. Romiplostim significantly improved treatment continuity. Eighty-four percent of patients receiving romiplostim required no CIT-related chemotherapy dose modifications during cycles 2 and

Long-term results from the phase 3 NCT01812902 tria suggest that extended pelvic lymph node dissection (ePLND) during radical prostatectomy may provide a significant survival benefit for patients with high-grade prostate cancer. The study enrolled 300 men with intermediate- or high-risk prostate cancer and followed them for a median of nearly 11 years. While extended lymph node

Results from the phase 3 RINGSIDE trial showed that varegacestat (AL102) significantly improved outcomes for patients with progressing desmoid tumors. The findings have supported a New Drug Application submitted to the FDA in April 2026. The global study enrolled 156 adults with desmoid tumors that had progressed within the previous year and randomly assigned them